Description
Azafen Pharmacodynamics
Tricyclic antidepressant from the group of non-selective inhibitors of neuronal takeover of monoamines. The mechanism of antidepressant action is associated with indiscriminate inhibition of neuronal reuptake of serotonin and norepinephrine, which leads to an increase in their concentrations in the CNS. Tholeptic action of the drug is combined with sedative activity and anxiolytic effect. It has practically no m-cholinoblocking activity and has no effect on monoamine oxidase (MAO) activity. It has no cardiotoxic effect.
Indications
Depressive episodes of mild to moderate severity (including chronic somatic diseases).
Contraindications
Hypersensitivity to the main and/or excipient components of the drug; severe hepatic and/or renal impairment; concomitant use of MAO inhibitors; pregnancy; lactation; children under 18 years of age (experience with medical use in children is limited). Rare hereditary problems of lactose intolerance, lactase deficiency, glucose-galactose malabsorption (the drug contains lactose).
Caution:
Chronic heart failure, myocardial infarction, coronary heart disease, condition after stroke, infectious diseases, diabetes mellitus (due to insufficient data on safety of use).
Dosage and administration
- Orally. The initial dose for adults is 25-50 mg in 2 intakes (in the morning and at lunchtime). If tolerated, the dose is gradually increased to 150-200 mg/day (in 3-4 doses, the last dose taken before bedtime), in some cases – up to 400 mg/day. The optimal daily dose is 150-200 mg, maximum 400-500 mg. When the desired effect is achieved, switch to maintenance doses: 25-75 mg/day. The course of treatment is up to 1 year (at least 1-1.5 months)
